Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Preliminary results from Sierra Oncology’s clinical trials of Sareum’s SRA737 compound due in H1 2019

US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update, it has made “substantial progress” with its two clinical development programmes for the compound
cancer cell
Chk1 controls a cancer cell's response to DNA damage

Preliminary results from two early-stage trials featuring Sareum Holdings PLC’s (LON:SAR) SRA737 checkpoint kinase 1 (Chk1) inhibitor cancer candidate are due to be published in the first half of 2019.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

READ: Sareum secures funding for drug programme

US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update it has made “substantial progress” with its two clinical development programmes for the compound.

Sierra is currently undertaking a Phase I/II monotherapy trial – i.e. SRA737 on its own – of the drug in patients with advanced cancer, as well as another Phase I/II study in which SRA737 is being combined with low-dose gemcitabine, one of the most commonly prescribed chemotherapies.

The NASDAQ-listed company said it has made “substantial progress” in recruiting patients with high grade serous ovarian cancer and that it expects to report preliminary efficacy results from these trials in the first half of next year.

Sierra has also been busy preparing for a third trial of SRA737 in combination with niraparib, a PARP inhibitor which stops cancer cells from repairing themselves, in prostate cancer patients, which is expected to begin within the next few months.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use